Related Experiment Video
Updated: Aug 13, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
[Venous thromboembolism and cancer]
M Pavic1, P Debourdeau, M Aletti
1Service de Médecine Interne, Hôpital d'Instruction des Armées Desgenettes, 108, boulevard Pinel, 69003 Lyon, France. m.pavic@chello.fr
La Revue De Medecine Interne
|January 18, 2006
Summary
Cancer patients face a higher risk of venous thrombosis, particularly with chemotherapy or advanced disease. While current treatments involve heparin, new oral anticoagulants may offer easier management in the future.
Area of Science:
- Oncology
- Hematology
- Vascular Medicine
Background:
- Cancer significantly elevates venous thrombosis risk, influenced by chemotherapy, surgery, and disease stage.
- Pathophysiology involves venous stasis, vessel damage, and hypercoagulability, with potential roles for platelet abnormalities and specific therapies.
- Current treatment for cancer-associated thrombosis favors low-molecular-weight heparin over oral anticoagulants, with inferior vena cava filters not indicated.
Purpose of the Study:
- To review the risk factors, pathophysiology, and current management of venous thrombosis in cancer patients.
- To discuss the implications of central venous catheters and prophylaxis strategies.
- To explore future therapeutic advancements in managing cancer-related thrombosis.
Main Methods:
- Literature review of existing studies on cancer-associated venous thrombosis.
- Analysis of risk factors, including patient-specific and treatment-related elements.
- Evaluation of current treatment guidelines and emerging therapeutic options.
Main Results:
- Venous thrombosis risk is substantially increased in cancer patients, impacting survival.
- Screening for malignancy in thrombosis patients should rely on comprehensive history and basic tests, not extensive screening.
- Low-molecular-weight heparin is the standard for treatment and prophylaxis, though not routinely recommended for all patients.
Conclusions:
- Newer oral anticoagulants show promise for simplifying the management of venous thrombosis in cancer patients in the near future.
- Further research is needed to integrate novel anticoagulants into clinical practice for this vulnerable population.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...